A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies |
| |
Authors: | Ana Maria Lopez Marsha Ketchum Heather Nichols Min-Jian Xu Yei-Mei Peng Robert Dorr David S Alberts |
| |
Institution: | (1) Section of Hematology and Oncology, Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA, US;(2) Arizona Cancer Center, College of Medicine, University of Arizona, 1515 N. Campbell Ave., Tucson, AZ 85724, USA Tel.: +1-520-6262271; Fax: +1-520-6262225, US |
| |
Abstract: | The effect of the addition of G-CSF to carboplatin, ifosfamide and doxorubicin (CIA) at the maximally tolerated dose (MTD)
was studied in a phase I clinical trial. Nine patients with incurable solid tumors were treated: six endometrial and epithelial
ovarian cancers, one colon cancer with pelvic masses and two unknown primary cancers. The carboplatin dose was calculated
using the Calvert formula and administered in a standard 30-min intravenous infusion. The initial carboplatin dose was AUC
4.0 mg/ml per min. Fixed doses of ifosfamide (1.25 g/m2 per day), mesna (1.0 g/m2 per day, and doxorubicin (15 mg/m2 per day) were combined and given as a 4-day continuous intravenous infusion in an attempt to decrease nonhematologic toxicity.
The dose-limiting toxicity of CIA was myelosuppression, mainly neutropenia and thrombocytopenia. Nonhematologic toxicities
were hemorrhagic cystitis, weakness, fatigue, and nausea and vomiting. The MTD for CIA was established at the first dose level
of carboplatin (4.0 mg/ml per min). Following this, G-CSF was added to the regimen in an unsuccessful effort to escalate the
carboplatin dose. Free and total carboplatin pharmacokinetics were determined using flameless atomic absorption spectroscopy.
There was one complete response and one partial response among eight evaluable patients. Both responding patients had advanced
ovarian cancer. We conclude that carboplatin dose intensification beyond an AUC of 4.0 mg/ml per min is not made feasible
by the addition of G-CSF to infusional doxorubicin and ifosfamide in patients with advanced gynecologic cancer.
Received: 22 December 1999 / Accepted: 28 April 2000 |
| |
Keywords: | Carboplatin Ifosfamide Doxorubicin G-CSF Combination regimen |
本文献已被 PubMed SpringerLink 等数据库收录! |
|